December 18, 2013 (Gold Coast, Australia): Today Griffith University, on their Alzheimer’s trial website, announced that the Griffith University Alzheimer’s Study has recently been granted full approval by the Human Research Ethics Committee as the first randomized double blind clinical trial to test perispinal etanercept for dementia in Australian patients. More information here, on the Griffith website. The INR congratulates Griffith University and its scientists and physicians for their diligence and outstanding efforts that have enabled the initiation of this new study. The approval and initiation of this new study represents independent scientific support for the scientific rationale underlying this treatment approach that was invented and pioneered at the INR in Los Angeles.
Branding
Mobile Header
